Download PDF
Arzneimittelforschung 2008; 58(6): 310-315
DOI: 10.1055/s-0031-1296512
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Pharmacokinetics of Doxycycline and Tissue Concentrations of an Experimental Long-acting Parenteral Formulation of Doxycycline in Wistar Rats

Dinorah Vargas-Estrada
1   Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia. Universidad Nacional Autónoma de México, Mexico City, Mexico
,
Lilia Gutiérrez
1   Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia. Universidad Nacional Autónoma de México, Mexico City, Mexico
,
Ivan Juarez-Rodríguez
1   Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia. Universidad Nacional Autónoma de México, Mexico City, Mexico
,
Héctor Sumano
1   Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia. Universidad Nacional Autónoma de México, Mexico City, Mexico
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)

    Permissions and Reprints

Abstract

Doxycycline hyclate (CAS 24390-14-5, doxycycline-h), an antibacterial with time-dependent action, was formulated as a non-irritating long-acting parenteral formulation based on a β-cyclodextrin: poloxamer-based matrix (doxycycline-h-LA). Tissue and serum concentrations vs time profile were investigated after its subcutaneous injection to Wistar rats. Serum concentration profiles and key pharmacokinetic (PK) variables of doxycycline-h-LA were compared to the corresponding profiles and PK values obtained with an aqueous formulation of doxycycline-h administered either intramuscularly, orally or intravenously to Wistar rats. In all groups, the dose was 10 mg/kg. Doxycycline-h-LA showed outstanding bioavailability (951% or 477% if a correction formula is considered), as compared to the one obtained with an aqueous formulation (106-82%, respectively). Corresponding values for maximum serum concentration were 3.19 µg/ml and 3.00 µg/ml, respectively, and elimination half-lives were completely different: 42.49 h and 2.77 h for doxycycline-h-LA and the aqueous formulation, respectively. Considering minimal inhibitory concentrations of doxycycline for sensitive and resistant bacteria (from ≤ 0.5 to ≥1.5 µg/ml), doxycycline-h-LA could be injected every 2 or 3 days, while aqueous doxycycline-h would require a dosing interval from 7.5 to 11 h. But if tissue concentrations are taken as braking points, the dosing interval will vary from 48 to 94 h. For doxycycline-h-LA, mean tissue:serum ratios were 2:1 for lungs, 9.8:1 for kidneys and 2.2:1 for intestine homogenates. These values are in close agreement with those found for the distribution of doxycycline in other species.

Key words

Antibacterials - CAS 24390-14-5 - Doxycycline, pharmacokinetics, rat, sustained-release
 

  • References

  • 1 Suzuka I, Kaji H, Kaji A. Binding of specific sRNA to 30S ribosomal subunits: effects of 50S ribosomal subunits. Proc Natl Acad Sci USA. 1966; 55: 1483-1486
    CrossrefPubMedGoogle Scholar
  • 2 Craig W. Pharmacokinetic-pharmacodynamic parameters: rationale for antibiotic use in mice and men. Clin Infect Dis. 1998; 6: 1-12
    PubMedGoogle Scholar
  • 3 Ole-Mapenay IM, Mitema ES, Mathio TE. Aspects of pharmacokinetics of doxycycline given to healthy and pneumonic east African dwarf goats by intramuscular injection. Vet Res Commun. 1997; 21: 453-62
    CrossrefPubMedGoogle Scholar
  • 4 Chopra I, Howe TGB, Linton KB, Richmond MH, Speller DCE. The tetracyclines: prospects at the beginning of the 1980s. J Antimicrob Chemother. 1981; 8: 5-21
    CrossrefPubMedGoogle Scholar
  • 5 Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit. 1982; 4: 115-135
    PubMedGoogle Scholar
  • 6 Prescott JF, Baggot JD, Walker RD. Antimicrobial Therapy in Veterinary Medicine. 3rd ed Ames (Iowa, USA): Iowa State University Press, Blackwell Scientific Publications; 2000. p 275-289
    Google Scholar
  • 7 Vomand KC, Sumano LH. Adverse drug reactions in cattle. JAVMA. 1990; 197: 899-905
    PubMedGoogle Scholar
  • 8 Meijer LA, Ceyssens KGF, De Greve BI, De Bruijn W. Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves. Vet Q. 1993; 15: 15-
    PubMedGoogle Scholar
  • 9 Riond JL, Tyezkowska K, Riviere JE. Pharmacokinetics and metabolic inertness of doxycycline in calves with mature or immature rumen function. Am J Vet Res. 1989; 50: 1329-1332
    PubMedGoogle Scholar
  • 10 Riond JL, Vaden SL, Riviere JE. Comparative pharmacokinetics of doxycycline in cats and dogs. J Vet Pharmacol Ther. 1990; 13: 415-24
    CrossrefPubMedGoogle Scholar
  • 11 Ziv G, Sulman FG. Analysis of pharmacokinetic properties of nine tetracycline analogues in dairy cow and ewes. Am J Vet Res. 1974; 35: 1197-201
    PubMedGoogle Scholar
  • 12 Bousquet E, Pommier P, Wessel-Robert S, Morvan H, Benoit-Valiergue H, Laval A. Efficacy of doxycycline in feed for the control of pneumonia caused by Pasteurella multocida and Mycoplasma hyopneumoniae in fattening pigs. Vet Rec. 1998; 143: 269-
    CrossrefPubMedGoogle Scholar
  • 13 Abd AM, Aty EL, Goudaha A, Zhoub HH. Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats. Pharmacol Res. 2004; 49: 487-491
    CrossrefPubMedGoogle Scholar
  • 14 Ole-Mapenay IM, Mitema ES. Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long acting formula. Vet Res Commun. 1995; 19: 425-32
    CrossrefPubMedGoogle Scholar
  • 15 Schach Von Wittenau M, Twomey TM. The disposition of doxycycline by man and dog. Chemotherapy. 1971; 16: 217-228
    CrossrefPubMedGoogle Scholar
  • 16 Whelton A, Schach von Wittenau M, Twomey TM, Walker WG, Bianchine JR. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int. 1974; 5: 365-371
    CrossrefPubMedGoogle Scholar
  • 17 Baumueller A, Madsen PO. Secretion of various antimicrobial substances in dogs with experimental bacterial prostatitis. Urol Res. 1977; 5: 215-218
    PubMedGoogle Scholar
  • 18 laffe JM, Poust RI, Feld SL, Colaizzi JL, Jaffe JM, Colaizzi JL, Poust RI. Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. J Pharm Sci. 1974; 8: 1256-1260
    PubMedGoogle Scholar
  • 19 Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJM. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm. 1991; 17: 1503-1549
    CrossrefPubMedGoogle Scholar
  • 20 Lawrence MJ. Surfactant systems microemulsions and vesicles as vehicles for drug delivery. Eur J Drug Metab Pharmacokinet. 1994; 19: 257-259
    CrossrefPubMedGoogle Scholar
  • 21 Bennett JV, Brodie JL, Benner EJ, Kirby WM. Simplified, accurate method for antibiotic assay of clinical specimens. J Appl Microbiol. 1966; 14: 170-177
    PubMedGoogle Scholar
  • 22 Cinquina AL, Longo F, Anastasi G, Giannetti L, Cozzani R. Validation of a high-performance liquid chromatography method for the determination of oxytetracycline, tetracycline, chlortetracycline and doxcycline in bovine milk and muscle. J Chromatogr A. 2003; 987: 227-233
    CrossrefPubMedGoogle Scholar
  • 23 Welling PG. Pharmacokinetics, Processes, Mathematics and applications. 2nd ed Washington DC: American Chemical Society; 1997. p 11-34
    Google Scholar
  • 24 Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed New York: Marcel Dekker; 1982. p 409
    Google Scholar
  • 25 Brayden DJ. Novel drug delivery strategies in veterinary medicine. Irish Vet J. 2003; 56: 310-316
    PubMedGoogle Scholar
  • 26 Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of Doxycycline. Clin Microbiol Infect. 2000; 6: 270-273
    CrossrefPubMedGoogle Scholar
  • 27 Yeruham I, Perl S, Sharony D, Vishinisky Y. Doxycycline toxicity in calves in two feedlots. J Vet Med B. 2002; 49: 406-408
    CrossrefPubMedGoogle Scholar
  • 28 Chiers K, Weyens P, Deprez P, Van Heerden M, Meulemans G, Baert K, Croubles S, De Backer P, Ducatelle R. Lingual and pharyngeal paralysis due to acute doxycycline intoxication in veal calves. Vet Rec. 2004; 155: 25-26
    CrossrefPubMedGoogle Scholar
  • 29 Inskeep PB, Darrington RT. Utilization of biopharmaceutical and pharmacokinetic principles in the development of veterinary controlled release drug delivery systems. In Rathbone MJ, Gurny R. editors Controlled Release Veterinary Drug Delivery. Amsterdam: Elsevier Science; 2000. p 1-15
    CrossrefGoogle Scholar
  • 30 Shaw DH, ST Rubin. Pharmacologic activity of doxycycline. J Am Vet Med Assoc. 1986; 189: 808-810
    PubMedGoogle Scholar
  • 31 Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline and oxytetracycline in dogs. Antimicrob Agents Chemother. 1975; 8: 713-720
    CrossrefPubMedGoogle Scholar
  • 32 Brook I, Elliott TB, Pryor HI, Sautter TE, Gnade BT, Thakar JH, Knudson GB. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents. 2001; 18: 559-562
    CrossrefPubMedGoogle Scholar
  • 33 Hospenthal DR, Murray CK. In vitro susceptibilities of seven Leptospira species to traditional and newer antibiotics. Antimicrob Agents Chemother. 2003; 47: 2646-2648
    CrossrefPubMedGoogle Scholar
  • 34 Guerin-Faublee V, Flandrois JP, Broye E, Tupin F, Richard Y. Actinomyces pyogenes: susceptibility of 103 clinical animal isolates to 22 antimicrobial agents. Vet Res. 1993; 24: 251-259
    PubMedGoogle Scholar
  • 35 Jee JB, Degraves FJ, Kim TY, Kaltenboeck B. High prevalence of natural chlamydophila species infection in calves. J Clin Microbiol. 2004; 42: 5664-5672
    CrossrefPubMedGoogle Scholar
  • 36 Yoshimura H, Ishimura M, Endoh YS, Kojima A. Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs. J Vet Med. 2001; 48: 555-560
    CrossrefPubMedGoogle Scholar
  • 37 Notari RE. Principles of pharmacokinetics: dosage regimen. In Notari RE. editor Biopharmaceutics and clinical pharmacokinetics - an introduction,. 4th ed New York: M. Dekker; 1987. p 45-212
    Google Scholar
  • 38 Riond JL, Riviere JE. Pharmacokinetics and toxicology of doxycycline. Vet Hum Toxicol. 1988; 30: 431-444
    PubMedGoogle Scholar
  • 39 Toutain PL, Bousquet-Mélou A. Bioavailability and its assessment. J Vet Pharmacol Ther. 2004; 27: 455-466
    CrossrefPubMedGoogle Scholar
  • 40 Vu XG, Nix DE, Gillikin S, Schentag GJ. Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. Antimic Agent Chemother. 1989; 33: 4-436
    PubMedGoogle Scholar